As AGGF1 abundance is reduced in patients and animal models with heart failure, we explored the potential of therapeutic treatment of cardiac hypertrophy and heart failure by targeted protein therapy via intravenous injection of recombinant AGGF1 (0.25 mg/kg BW). This evidence concerns the gene AGGF1 and cardiac hypertrophy.